Evidence map›Paper›PMID 39533335›Full record

ArticleAddiction science & clinical practice2024

HIV pre-exposure prophylaxis programmatic preferences among people who inject drugs: findings from a discrete choice experiment.

William H Eger, Angela R Bazzi, Chad J Valasek, Carlos F Vera, Alicia Harvey-Vera, Steffanie A Strathdee, Heather A Pines

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Addiction science & clinical practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

William H EgerSchool of Medicine, University of California, San Diego, La Jolla, San Diego, CA, USA.
Angela R BazziHerbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla, San Diego, CA, USA.
Chad J ValasekHerbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla, San Diego, CA, USA.
Carlos F VeraSchool of Medicine, University of California, San Diego, La Jolla, San Diego, CA, USA.
Alicia Harvey-VeraSchool of Medicine, University of California, San Diego, La Jolla, San Diego, CA, USA.
Steffanie A StrathdeeSchool of Medicine, University of California, San Diego, La Jolla, San Diego, CA, USA.
Heather A PinesSchool of Medicine, University of California, San Diego, La Jolla, San Diego, CA, USA. hpines@sdsu.edu.ORCID 0000-0002-7173-1981

Funding

VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUSAN JANET LITTLE · 1994 to 2026
$78.4M
Ethno-epidemiology of HCV, HIV and Overdose associated with Drug Marketsand Drug TourismR01DA049644 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI STRATHDEE, STEFFANIE A. · 2020 to 2024
$8.2M
Training Program in Substance Use, HIV and Related InfectionsT32DA023356 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Natasha Martin, Steffanie A Strathdee · 2007 to 2026
$7.8M
Preventing HIV infection among people who inject drugs during COVID-19K01DA043412 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BAZZI, ANGELA ROBERTSON · 2017 to 2021
$934k
Center for AIDS Research, University of California, San Diego P30AI036214NIAID NIH HHS P30 AI036214NIDA NIH HHS 3K01DA043412-04S1NIDA NIH HHS K01 DA043412NIDA NIH HHS K01DA043412NIDA NIH HHS R01 DA049644NIDA NIH HHS R01DA049644-S1NIDA NIH HHS R01DA049644-S2NIDA NIH HHS T32 DA023356NIDA NIH HHS T32DA023356
6 · The paper itself

Abstract

backgroundPre-exposure prophylaxis (PrEP) holds promise for decreasing new HIV infections among people who inject drugs (PWID), yet daily oral PrEP use is low, and PrEP modality and delivery strategy preferences in this population remain understudied.

methodsFrom May 2022-June 2023, we conducted a discrete choice experiment (DCE) with PWID in San Diego, California. Participants viewed 18 PrEP program scenarios in sets of three and chose their preferred scenario within each set. Scenarios consisted of various combinations of five characteristics: PrEP modality (injectable, implantable, oral), frequency of use (annual, bi-monthly, daily), service location (community-based organization, clinic, telemedicine), prescription access location (on-site, street outreach, mail), and adherence supports (social support, outreach worker, phone/text reminder). Multinomial logit regression estimated probabilities of choosing PrEP program scenarios as a function of the five characteristics to estimate part-worth utility scores (PWUS; reflecting relative preferences for specific characteristic values) and relative importance scores (RIS; reflecting the relative influence of each characteristic on program choice). We also explored differences by hypothesized modifiers of preferences (i.e., sex assigned at birth, housing status, injection frequency, prior PrEP awareness).

resultsAmong 262 participants, mean age was 43.1 years, and most reported male sex assigned at birth (69.5%), identified as non-Hispanic (60.3%), and were previously unaware of PrEP (75.2%). Frequency of use (RIS: 51.5) and PrEP modality (RIS: 35.3) had the greatest influence on PrEP program choice. Within these characteristics, participants had relative preferences for annual use (PWUS: 0.83) and oral PrEP (PWUS: 0.57), and relative aversions to daily use (PWUS: -0.76) and implantable PrEP (PWUS: -0.53). Generally, participants did not indicate preferences for specific service or prescription access locations, or adherence supports; however, among those with prior PrEP awareness, prescription access location and adherence supports had a slightly greater influence on PrEP program choices.

conclusionOur study considered diverse PrEP scenarios and highlighted potential preferences for long-acting oral modalities. Although not currently available, renewed investment in long-acting oral PrEP formulations may facilitate PrEP care engagement among PWID. Additional delivery and implementation strategy research is needed to support PrEP uptake and persistence in this population.

Indexed as

HIV InfectionsPatient PreferencePre-Exposure ProphylaxisSubstance Abuse, IntravenousAdultAnti-HIV AgentsCaliforniaChoice BehaviorFemaleHumansMaleMiddle AgedAnti-HIV AgentsCommunity health servicesDiscrete choice experimentIntravenousPre-exposure prophylaxisPrescriptionsSubstance abuseTelemedicine

Identifiers

PMID39533335
PMCPMC11555929

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.